Vitamin B12 is one of the best-characterized nutrients in medicine, with a clear role in deficiency. This page distinguishes what the evidence firmly supports from claims that outrun it.
Overview
B12 is the opposite case from most compounds on this site: the evidence is enormous, old, and settled — for one thing. Correcting a genuine deficiency works, reliably and often dramatically. Almost everything else attributed to B12, including the energy and mood benefits that sell injections and IV drips, either has not been demonstrated in people with adequate B12 status or has been tested and failed. The single most useful question when reading any B12 study is whether its participants were deficient at baseline.
What is firmly established
B12 (cobalamin) is a required cofactor for methionine synthase and methylmalonyl-CoA mutase, and therefore for DNA synthesis, myelin maintenance, and red-cell production. Deficiency produces recognised clinical syndromes: megaloblastic anaemia, and a neurological picture including peripheral neuropathy and subacute combined degeneration of the spinal cord, which can become irreversible if untreated. Repletion corrects the haematologic abnormalities and often the neurological ones, depending on how long the deficiency persisted. Sally Stabler's clinical-practice review in the New England Journal of Medicine (2013) is the standard summary of diagnosis and management (PubMed 23301732).
None of this is contested. It is the reason injectable cyanocobalamin and hydroxocobalamin are approved prescription treatments rather than wellness products.
Who actually becomes deficient
O'Leary and Samman's review in Nutrients (2010), Vitamin B12 in Health and Disease, sets out the two mechanisms: limited dietary intake of animal foods, and malabsorption. The second is the more common cause in older adults, typically secondary to gastric achlorhydria, and it is why oral intake can be adequate while status is not. Vegetarians and vegans, people on long-term metformin or acid-suppressing drugs, and those with pernicious anaemia or gastrointestinal surgery are the recognised risk groups.
The review also notes that subclinical deficiency often produces subtle symptoms that go unrecognised, and raises possible long-term associations with pregnancy outcomes and vascular, cognitive, bone, and eye health — framed there as areas of concern, not established causal effects.
Where the evidence runs out
- Energy in replete people. There is no trial evidence that supplemental B12 increases energy or reduces fatigue in people with normal status. The perception that it does comes from the genuine and sometimes rapid improvement seen when a deficient person is treated.
- Cardiovascular outcomes. B12 with folate reliably lowers homocysteine. The O'Leary and Samman review notes that recent trials did not show the expected reductions in cardiovascular risk — a textbook example of a biomarker moving without the outcome following.
- Cognition. Supplementation in people without deficiency has not been shown to prevent cognitive decline.
- Athletic performance. No consistent effect in B12-replete athletes.
- Injections versus oral. For most causes of deficiency, high-dose oral repletion is effective; injections are chiefly a matter of adherence and severe malabsorption, not superior potency.
How to read a B12 claim
B12 has low toxicity — excess is largely excreted, and no tolerable upper intake level has been set — which is why high-dose products are common and why "it can't hurt" is the usual argument for them. The stronger objection is diagnostic rather than toxicological: supplementing before testing can normalise a serum B12 result and mask the underlying cause, and a symptomatic neurological deficiency is a condition worth identifying properly. Serum B12 alone is an imperfect marker; methylmalonic acid and homocysteine are the confirmatory tests the clinical literature relies on.